OpenEvidence: Most physicians quietly use this medical AI tool
OpenAI launched ChatGPT for Clinicians in April without licensing NEJM or JAMA. OpenEvidence has both, and the market repriced it from $1B to $12B in 15 months on the back of 65% US physician reach and 27 million April clinical encounters. The binding constraint for entering credentialed verticals was never model quality; it was licensed-data governance and the operational-regime approval that comes with it. The Deployment Company and the LF Networking pattern this week are structurally identical: the moat that holds isn't capability, it's the layer of credential, distribution, or implementation sitting above it. For frontier labs, that means the verticals with the clearest content-licensing moats (clinical, legal, financial) will reprice fastest against whoever shows up without the corpus.